Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$5.61M$5.61M+574.2% vs Q1 2022 Net Income-$81.02M-$81.02MN/M vs Q1 2022 EPS Diluted-$1.47-$1.47N/M vs Q1 2022 Operating Income-$90,613,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$95,582,000N/M Margins · derivedOperating margin-1615.5%+10541.4 pt vs Q1 2022
Net margin-1444.4%+9946.7 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end